Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	MAP2K1 Q56P
Gene Variant Detail	MAP2K1 Q56P (gain of function)
Relevant Treatment Approaches	MEK inhibitor (Pan) MEK1 Inhibitor

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 18 of 18 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
MAP2K1 Q56P	Erdheim-Chester disease	predicted - sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Cobimetinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875).	26566875
MAP2K1 Q56P	Erdheim-Chester disease	predicted - sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 Q56P (PMID: 30867592; NCT01953926).	30867592
MAP2K1 Q56P	stomach cancer	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).	22327936
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Advanced Solid Tumor	resistant	MEK1 Inhibitor	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Advanced Solid Tumor	resistant		Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Advanced Solid Tumor	resistant		GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Advanced Solid Tumor	resistant	MEK inhibitor (Pan) MEK1 Inhibitor	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Advanced Solid Tumor	sensitive		PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	lung cancer	predicted - sensitive		LY3214996	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line harboring MAP2K1 Q56P was sensitive to treatment with LY3214996 in culture, demonstrating decreased cell proliferation (PMID: 31744895).	31744895
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited colony formation of transformed cells expressing MAP2K1 Q56P in culture (PMID: 25351745).	25351745
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 Q56P in culture (PMID: 36442478).	36442478
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 Q56P in culture (PMID: 32641410).	32641410
MAP2K1 Q56P	lung adenocarcinoma	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	lung adenocarcinoma	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Selumetinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Selumetinib (AZD6244), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	lung adenocarcinoma	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Refametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	lung adenocarcinoma	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Mirdametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Gomekli (mirdametinib), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	stomach cancer	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Preclinical	Actionable	In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).	26582713

Showing 1 to 18 of 18 entries

Filter rows: